The Motley Fool··Eric VolkmanAbbott Slashes 2026 Guidance After Q1 Beat, Exact Sciences Deal Weighs on Stock
Abbott met Q1 expectations with $11.2B revenue but cut full-year EPS guidance due to share dilution from Exact Sciences acquisition, triggering 6% stock decline.
ABTguidance cutmedical devices